Search clinical trials for: GSK1144814

Total 4 results

GlaxoSmithKline

Completed

A Repeat Dose Positron Emission Tomography Study With GSK1144814 (NK1 NK3 PET)

Schizophrenia

United Kingdom
GlaxoSmithKline

Completed

Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (MNK112891)

Schizophrenia

Australia
GlaxoSmithKline

Completed

First Time in Human Study (FTIH) With Positron Emission Tomography (PET)

Schizophrenia

United Kingdom
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Withdrawn

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study (NT-814)

Opioid Use Disorder

United States

3

Subscribe